Cogent Bioscience (COGT) Files New Drug Application For Bezuclastinib

Cogent Biosciences Inc. (NASDAQ:COGT) is one of the 10 affordable biotech stocks to buy right now.

On June 30, Cogent Bioscience Inc. (NASDAQ:COGT) disclosed that it filed a New Drug Application for bezuclastinib, a drug for the treatment of Advanced Systemic Mastocytosis. The application to the U.S. FDA is backed by encouraging clinical results from the APEX key trial.

Sergey Nivens/Shutterstock.com

Cogent’s President and Chief Executive Officer, Andrew Robbins, stated that they are currently engaging closely with the FDA on each of its three submissions. He remains optimistic that bezuclastinib will attain its initial approvals by the end of 2026. He also acknowledged the efforts of the company’s development team, stating:

“I’d also like to congratulate our small, but exceptionally talented, Cogent development team, whose amazing work analyzing, presenting and submitting data from three pivotal trials in less than twelve months has rapidly positioned the company to achieve our vision of creating best-in-class therapies for patients fighting rare, mutational driven diseases.”

Back in mid-June, the company revealed preclinical findings for its innovative JAK2 V617F mutation-specific inhibitor at the European Hematology Association Congress 2026. Robbins stated that this selective inhibitor has the ability to target the underlying mutational cause of a disease while also reducing the off-target blood-related impacts. He added that they are currently expediting the program and also plan to file the Investigational New Drug application in 2026.

Cogent Biosciences Inc. (NASDAQ:COGT) is a clinical-stage biotechnology company that develops precision therapeutics for genetically defined illnesses. The company’s lead therapeutic candidate, bezuclastinib, is a selective tyrosine kinase inhibitor nearing a Phase 3 trial. It is designed to target KIT receptor mutations involved in systemic mastocytosis and advanced gastrointestinal stromal tumors.

While we acknowledge the risk and potential of COGT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than COGT and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1